Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 1mg (95% Untagged Premium)

ACE-031 1mg (95% Untagged Premium) Research Handling Note: For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolut

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

ACE-031 1mg (95% Untagged Premium)

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately.

Stock: 96

Model: ACE-031 1mg

Molecular Formula: C133H227N43O33

SKU: ACE1-024

Research Only: Yes

Certificate of analysis

Description

Technical Data

ACE-031 1mg - High-Quality Research Peptide

ACE-031, offered at 1mg, is a high-quality, specialised research peptide developed for advanced scientific exploration in muscle physiology. This product is ideal for laboratory settings where precision and reliability are paramount.

Product Name: ACE-031 1mg

Catalogue Number: ACE1-024

Molecular Weight: 2956.5 g/mol

Purity: 95%

Sequence: TBC

Form: Lyophilised Solid

Usage and Storage:

ACE-031 is supplied as a lyophilised solid to ensure maximum stability and ease of use in research environments. For best results, follow our website's detailed reconstitution and storage guidelines.

Synthesis and Quality Assurance:

ACE-031 is meticulously synthesised through a controlled process that guarantees high purity and stability, making it suitable for precise scientific studies. Our commitment to excellence ensures that each batch undergoes stringent quality control to meet the rigorous standards researchers require.

Legal and Safety Information:

UK-Peptides proudly provides ACE-031 strictly for scientific and research use. In alignment with our dedication to supporting the research community, we ensure our products meet stringent quality standards and legal requirements. Please note that our peptides, including ACE-031, are not designed for human consumption or clinical application.

If you require high-quality ACE-031 for your research in the UK, explore our range of peptides designed for scientific rigour and innovation.

Identification

Molecular Weight (g/mol)

2956.5 g/mol

Peptide Sequence

TBC

Product Name

ACE-031 1mg

Catalogue Number

ACE1-024

CAS Number

N/A (recombinant fusion protein, not a registered CAS peptide)

Physical and Chemical Properties

Molecular Formula

C133H227N43O33

Form

Lyophilised solid

Appearance

White to off-white lyophilised powder

Melting Point

Not applicable (decomposes before melting)

Analytical and Quality Control

Mass Spectrum

Conforms to specification (consistent with theoretical MW 2956.5 g/mol)

Purity %

≥95% (HPLC)

Amino Acid Composition

Consistent with the theoretical peptide/protein sequence

Research Use and Safety

Caution

Handle using appropriate PPE and in compliance with relevant laboratory safety standards

Intended Use

For laboratory research use only. Not for human or veterinary use.

Hazard Classification

Not classified as hazardous under GHS for research quantities

Storage, Handling and Stability

Storage Temperature, Opened

–20 °C, minimise freeze–thaw cycles

Storage Temperature, Unopened

–20 °C recommended for long-term storage

Shelf Life

2 years unopened under recommended conditions

Reconstitution Stability

Stable for up to 28 days at 2–8 °C in aqueous solution under sterile conditions

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Comparison with Other Myostatin Inhibition Approaches in ALS Research

ACE-031 is one of several myostatin pathway inhibitors that have been investigated in ALS or related muscle-wasting contexts. Key comparators include: Anti-myostatin antibodies (landogrozum…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

ACE-031 and Bone Density Research: Myostatin Inhibition, Skeletal Remodelling and Osteoporosis Biology UK 2026

Research Use Only. Not for human use. All content on this page relates strictly to preclinical and in vitro research findings. ACE-031 — the fusion protein combining the extracellular domain of ActRIIB (Activin Receptor Type IIB) with human IgG1 Fc — is primarily recognised in research contexts as a myostatin and activin ligand trap with potent muscle-anabolic effects. However, the biology of the ActRIIB-ligand system extends substantially beyond skeletal muscle into bone metabolism, where the same ligands — myostatin (GDF-8), activin A, GDF-11 and BMP9 — regulate osteoblast and osteoclast activity with important implications for bone density and fracture biology. This post examines the mechanistic connections between ActRIIB ligand trapping, skeletal remodelling and osteoporosis research.

Source: peptideslabuk.com ↗

Research Indications

Phase 1 data showed statistically significant lean mass increases (average +1.7%) after a single IV dose in healthy postmenopausal women. Phase 2 trial in DMD patients showed improvements in lean body mass and bone mineral density, but trial was halted due to vascular adverse events. Preclinical models demonstrate robust prevention of muscle loss in disease states through myostatin pathway inhibition. Phase 1 trial subjects showed concurrent fat mass reductions alongside lean mass gains, suggesting favorable nutrient partitioning. DMD trial data showed increases in bone mineral density, consistent with known effects of ActRIIB pathway modulation on bone metabolism.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 (1 mg) Dosage Protocol

A soluble activin receptor type IIB (ActRIIB) Fc-fusion protein that traps myostatin and related muscle-limiting factors. Its clinical development was halted for safety. Research-use-only — this page is an educational reference and a caution, not a dosing recommendation.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →